Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

被引：6

作者：

Usmani, Saad Z. ^{[1
]}

Nahi, Hareth ^{[2
]}

Mateos, Maria-Victoria ^{[3
]}

Lokhorst, Henk M. ^{[4
]}

Chari, Ajai ^{[5
]}

Kaufman, Jonathan L. ^{[6
]}

Moreau, Philippe ^{[7
]}

Oriol, Albert ^{[8
]}

Plesner, Torben ^{[9
,10
,11
]}

Benboubker, Lotfi ^{[12
]}

Hellemans, Peter ^{[13
]}

Masterson, Tara ^{[14
]}

Clemens, Pamela L. ^{[15
]}

Ahmadi, Tahamtan ^{[15
]}

Liu, Kevin ^{[16
]}

San-Miguel, Jesus ^{[17
]}

机构：

[1] Levine Canc Inst Carolinas HealthCare Syst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[2] Karolinska Univ Hosp, Karolinska Inst, Div Hematol, Huddinge, Sweden

[3] Univ Hosp Salamanca IBSAL, Salamanca, Spain

[4] Vrije Univ Amsterdam Med Ctr, Dept Hematol, Amsterdam, Netherlands

[5] Tisch Canc Inst, Mt Sinai Sch Med, New York, NY USA

[6] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[7] Nantes Univ Hosp, Dept Hematol, Nantes, France

[8] HGTiP, Inst Catala Oncol, Barcelona, Spain

[9] Univ So Denmark, Vejle Hosp, Ctr Little Belt, Dept Hematol, Vejle, Denmark

[10] Vejle Hosp, Dept Hematol, Vejle, Denmark

[11] Univ So Denmark, Vejle, Denmark

[12] CHU Tours Hop Bretonneau, Tours, France

[13] Janssen Res & Dev, Beerse, Belgium

[14] Janssen Res & Dev, Spring House, PA USA

[15] Janssen Res & Dev, LLC, Spring House, PA USA

[16] Janssen Res & Dev, LLC, Raritan, NJ USA

[17] Clin Univ Navarra CIMA, IDISNA, Pamplona, Spain

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.1149.1149

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1149

引用

页数：6

共 50 条

[31] Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma
Lokhorst, Henk M.
Plesner, Torben
Gimsing, Peter
Nahi, Hareth
Minnema, Monique
Lassen, Ulrik Niels
Krejcik, Jakub
Laubach, Jacob
Lisby, Steen
Basse, Linda
Richardson, Paul Gerard Guy
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[32] Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma
Shibayama, Hirohiko
Matsumoto, Morio
Kosugi, Hiroshi
Shibayama, Kazuhiro
Yamazaki, Hiroshi
Iida, Shinsuke
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (01) : 112 - 121
[33] Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma
Hirohiko Shibayama
Morio Matsumoto
Hiroshi Kosugi
Kazuhiro Shibayama
Hiroshi Yamazaki
Shinsuke Iida
International Journal of Hematology, 2021, 113 : 112 - 121
[34] Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study
Vij, Ravi
Savona, Michael
Siegel, David S.
Kaufman, Jonathan L.
Badros, Ashraf
Ghobrial, Irene M.
Paner, Agne
Jagannath, Sundar
Jakubowiak, Andrzej
Mikhael, Joseph R.
Kapoor, Prashant
Neuman, Linda L.
Lee, Ju RueyJiuan
Berdeja, Jesus G.
BLOOD, 2014, 124 (21)
[35] Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study
Ghobrial, Irene M.
Weller, Edie
Vij, Ravi
Munshi, Nikhil C.
Banwait, Ranjit
Bagshaw, Meghan
Schlossman, Robert
Leduc, Renee
Chuma, Stacey
Kunsman, Janet
Laubach, Jacob
Jakubowiak, Andrzej J.
Maiso, Patricia
Roccaro, Aldo
Armand, Philippe
Dollard, Akari
Warren, Diane
Harris, Brianna
Poon, Tiffany
Sam, Amy
Rodig, Scott
Anderson, Kenneth C.
Richardson, Paul G.
LANCET ONCOLOGY, 2011, 12 (03): : 263 - 272
[36] Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 (CLR 131) in Patients with Relapsed or Refractory Multiple Myeloma
Longcor, Jarrod
Oliver, Kate
BLOOD, 2019, 134
[37] Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study
Rodriguez-Otero, Paula
Dholaria, Bhagirathbhai
Askari, Elham
Reece, Donna E.
van de Donk, Niels W. C. J.
Chari, Ajai
Goldschmidt, Hartmut
Krishnan, Amrita Y.
Martin, Thomas
Mateos, Maria-Victoria
Giles, Daniel Morillo
Rodriguez, Cesar
Rosinol, Laura
San-Miguel, Jesus F.
Sureda, Anna
Waesch, Ralph
Weisel, Katja
Verona, Raluca I.
Lin, Shun Xin Wang
Prior, Thomas J.
Weiss, Brendan M.
Wade, Mark
Goldberg, Jenna D.
Oriol, Albert
Hari, Parameswaran
BLOOD, 2021, 138
[38] Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study
Larocca, Alessandra
Montefusco, Vittorio
Bringhen, Sara
Rossi, Davide
Crippa, Claudia
Mina, Roberto
Galli, Monica
Marcatti, Magda
La Verde, Giacinto
Giuliani, Nicola
Magarotto, Valeria
Guglielmelli, Tommasina
Rota-Scalabrini, Delia
Omede, Paola
Santagostino, Alberto
Baldi, Ileana
Carella, Angelo Michele
Boccadoro, Mario
Corradini, Paolo
Palumbo, Antonio
BLOOD, 2013, 122 (16) : 2799 - 2806
[39] MagnetisMM-30: A Phase 1B, Open-Label Study of Elranatamab in Combination With Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Lesokhin, Alexander
Raza, Muhammed
Acosta, Jorge
Mueller, Patrick Y.
O'Connell, Ashleigh
Yver, Anne
Lou, Carolyn
Finn, Gregory
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S187 - S187
[40] MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).
Lesokhin, Alexander M.
Raza, Muhammed Saleem
Acosta, Jorge
Muller, Patrick
O'Connell, Ashleigh
Yver, Anne
Lou, Carolyn
Finn, Gregory
Service, Myeloma
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →